Transcriptional control: An essential component of cancer gene therapy strategies?

被引：40

作者：

Harrington, KJ ^{[1
]}

Linardakis, E ^{[1
]}

Vile, RG ^{[1
]}

机构：

[1] Mayo Clin, Program Mol Med, Rochester, MN 55902 USA

来源：

ADVANCED DRUG DELIVERY REVIEWS | 2000年 / 44卷 / 2-3期

关键词：

enhancer; gene therapy; tissue specific promoter; tumor specific promoter; inducible promoter; customized promoter;

D O I：

10.1016/S0169-409X(00)00093-4

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The therapeutic index of cancer gene therapy approaches will, at least in part, be dictated by the spatial and temporal control of expression of the therapeutic transgenes. Strategies which allow precise control of gene transcription are likely to play a crucial role in the future pre-clinical and clinical development of gene therapy. In this review, we discuss these issues as they relate to tissue and tumor specific promoters. In addition, the exciting opportunities offered by the development of regulated gene expression systems using small molecules, radiation and heat are reviewed. It is realistic to expect that the future offers the prospect of amalgamating elements of a number of these different systems in a co-ordinated gene delivery approach with the potential to increase the efficacy and reduce the toxicity of treatment. (C) 2000 Elsevier Science B.V. All rights reserved.

引用

页码：167 / 184

页数：18

共 117 条

[1] Ligand-dependent regulation of plasmid-based transgene expression in vivo [J].